All In Biotech

Drug Trial Radar · NCT03872401

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 12,301 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,301

Actual

Start

Jun 11, 2019

Primary completion

Jul 25, 2025

Study completion Jul 25, 2025

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

Conditions

  • Coronary Heart Disease (CHD)

Interventions

  • EvolocumabDrug

    Administered subcutaneously using an autoinjector pen.

  • PlaceboDrug

    Administered subcutaneously using an autoinjector pen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred FirstTime frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
  2. Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred FirstTime frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

Locations

852 sites in 33 countries. Site status is shown where the registry gives one.

  • North Alabama Research Center LLC

    Athens, Alabama

  • Cardiovascular Associates

    Birmingham, Alabama

  • Heart Center Research LLC

    Huntsville, Alabama

  • Mobile Heart Specialists PC

    Mobile, Alabama

  • Arkansas Cardiology

    Little Rock, Arkansas

  • Central Arkansas Veterans Healthcare System

    Little Rock, Arkansas

  • Cardiovascular Research Foundation of Southern California

    Beverly Hills, California

  • Westside Medical Associates of Los Angeles

    Beverly Hills, California

  • West Coast Research LLC

    Dublin, California

  • Desert Oasis Healthcare Medical Group

    Palm Springs, California

  • Covigilant Research, LLC

    Riverside, California

  • Sierra Clinical Research

    Roseville, California

  • Center for Clinical Trials of Sacramento Inc

    Sacramento, California

  • Harbor University of California Los Angeles Medical Center

    Torrance, California

  • Optumcare Colorado Springs LLC

    Colorado Springs, Colorado

  • University of Colorado Memorial Health System

    Colorado Springs, Colorado

  • New West Physicians

    Golden, Colorado

  • South Denver Cardiology Associates

    Littleton, Colorado

  • Cardiology Associates of Fairfield County, PC

    Stamford, Connecticut

  • Excel Medical Clinical Trials

    Boca Raton, Florida

  • Bay Area Cardiology

    Brandon, Florida

  • Nature Coast Clinical Research LLC

    Crystal River, Florida

  • Daytona Heart Group

    Daytona Beach, Florida

  • Cardiology Research Associates

    Daytona Beach, Florida

  • Complete Health Research

    DeLand, Florida

  • Cohen Medical Associates PA

    Delray Beach, Florida

  • Jellinger and Lerman MD PA dba The Center for Diabetes and Endocrine Care

    Fort Lauderdale, Florida

  • George E Platt MD

    Green Cove Springs, Florida

  • Research Physicians Network Alliance

    Hollywood, Florida

  • University of Florida and Shands Hospital

    Jacksonville, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • First Coast Cardiovascular Institute PA

    Jacksonville, Florida

  • Baptist Health Research Institute

    Jacksonville Beach, Florida

  • Gad Research Center

    Miami, Florida

  • Cardiovascular Research Center of South Florida

    Miami, Florida

  • Ocala Research Institute, Inc

    Ocala, Florida

  • Cardiology Consultants

    Pensacola, Florida

  • Charlotte Heart Group Research Center

    Port Charlotte, Florida

  • Intercoastal Medical Group

    Sarasota, Florida

  • Cardiovascular Center of Sarasota

    Sarasota, Florida

Showing 40 of 852 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.